{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T17:36:14Z","timestamp":1790357774272,"version":"4.1.0"},"reference-count":30,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,8,14]],"date-time":"2024-08-14T00:00:00Z","timestamp":1723593600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Genet."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Fabry disease is a rare X-linked lysosomal storage disorder caused by \u03b1-galactosidase A (\u03b1-Gal A) deficiency. Reduced or absent enzyme activity causes progressive lysosomal accumulation of globotriaosylceramide (Lyso-Gb3) in various cells throughout the body to trigger inflammation and fibrosis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Case description<\/jats:title><jats:p>We present the first familial case of Fabry Disease in North Macedonia identified based on clinical manifestations and confirmed through enzyme, biomarker, and genetic tests. The index case in the family was a 45-year-old male undergoing hemodialysis therapy. He has had chronic burning uncontrolled limb pain since childhood, intermittent abdominal cramps, anhidrosis, and hypertension. The constellation of clinical presentations accompanied by similar symptoms in close family members prompted the enzyme, biomarker, and genetic analyses for Fabry disease. Genetic testing identified a known pathogenic <jats:italic>GLA<\/jats:italic> missense variant c.443G&amp;gt;A or p.(Ser148Asn) in the hemizygous state. Subsequent family studies allowed identification of another hemizygous male and five heterozygous female carriers affected by this X-linked disorder.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>We report identification of the first familial case of Fabry disease in North Macedonia and describe the phenotype associated with the Ser148Asn <jats:italic>GLA<\/jats:italic> variant. Greater awareness of this rare disease linked to continuous medical education is crucial for timely diagnosis and treatment.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fgene.2024.1415906","type":"journal-article","created":{"date-parts":[[2024,8,14]],"date-time":"2024-08-14T06:06:00Z","timestamp":1723615560000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Case report: First diagnosis of Fabry disease in North Macedonia in a patient presenting with kidney failure on hemodialysis"],"prefix":"10.3389","volume":"15","author":[{"given":"Nikola","family":"Gjorgjievski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vlatko","family":"Karanfilovski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todor","family":"Arsov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pavlina Dzekova","family":"Vidimliski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Galisna Severeova","family":"Andreevska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gjulshen","family":"Selim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petar","family":"Dejanov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasilena","family":"Jordanova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivelina","family":"Marinova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emil","family":"Paskalev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Igor G.","family":"Nikolov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,8,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1111\/j.1365-2133.1898.tb16317.x","article-title":"A case of \u201cangeio\u2010keratoma.\u201d","volume":"10","author":"Anderson","year":"1898","journal-title":"Br. J. Dermatology"},{"key":"B2","first-page":"227","article-title":"Fabry disease: twenty-two novel mutations in the alpha-galactosidase A gene and genotype\/phenotype correlations in severely and mildly affected hemizygotes and heterozygotes","volume":"48","author":"Ashton-Prolla","year":"2000","journal-title":"J. investigative Med."},{"key":"B4","doi-asserted-by":"publisher","first-page":"e37048","DOI":"10.7759\/cureus.37048","article-title":"Fabry disease and its management: a literature analysis","volume":"15","author":"Besekar","year":"2023","journal-title":"Cureus"},{"key":"B5","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s13023-015-0253-6","article-title":"Recommendations for initiation and cessation of enzyme replacement therapy in patients with Fabry disease: the European Fabry Working Group consensus document","volume":"10","author":"Biegstraaten","year":"2015","journal-title":"Orphanet J. rare Dis."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.2298\/vsp200228071c","article-title":"Fabry disease in Serbia: current status and future perspectives","volume":"79","author":"\u0106eli\u0107","year":"2022","journal-title":"Vojnosanit. Pregl."},{"key":"B7","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1007\/s00467-021-05076-x","article-title":"Fabry disease and kidney involvement: starting from childhood to understand the future","volume":"37","author":"Chimenz","year":"2022","journal-title":"Pediatr. Nephrol."},{"key":"B3","unstructured":"ClinVar aggregates information about genomic variation and its relationship to human health2024"},{"key":"B8","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/B978-0-12-813955-4.00042-8","article-title":"Fabry disease: \u03b1-galactosidase A deficiency","volume-title":"InRosenberg's molecular and genetic basis of neurological and psychiatric disease","author":"Desnick","year":"2020"},{"key":"B9","doi-asserted-by":"publisher","first-page":"3726","DOI":"10.3390\/ijms19123726","article-title":"Mutations in the GLA gene and LysoGb3: is it really Anderson-Fabry disease?","volume":"19","author":"Duro","year":"2018","journal-title":"Int. J. Mol. Sci."},{"key":"B10","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/bf01986897","article-title":"Losa haemorrhagica Hebrae","volume":"43","author":"Fabry","year":"1898","journal-title":"Arch. f\u00fcr Dermatol. Syph."},{"key":"B11","article-title":"Fabry disease\u2013clinical review rare, but not so rare! Macedonian","volume":"7","author":"Gjorgjievski","year":"2023","journal-title":"J. Anaesth"},{"key":"B12","doi-asserted-by":"publisher","first-page":"31","DOI":"10.3390\/ijns9020031","article-title":"Newborn screening for Fabry disease: current status of knowledge","volume":"9","author":"Gragnaniello","year":"2023","journal-title":"Int. J. Neonatal Screen."},{"key":"B13","doi-asserted-by":"publisher","first-page":"440","DOI":"10.3238\/arztebl.2009.0440","article-title":"Fabry disease\u2014often seen, rarely diagnosed","volume":"106","author":"Hoffmann","year":"2009","journal-title":"Dtsch. \u00c4rzteblatt Int."},{"key":"B14","doi-asserted-by":"publisher","first-page":"e035182","DOI":"10.1136\/bmjopen-2019-035182","article-title":"Early indicators of disease progression in Fabry disease that may indicate the need for disease-specific treatment initiation: findings from the opinion-based PREDICT-FD modified Delphi consensus initiative","volume":"10","author":"Hughes","year":"2020","journal-title":"BMJ Open"},{"key":"B15","first-page":"15","article-title":"Fabry disease. A case report","volume":"14","author":"Kotnik","year":"2005","journal-title":"Acta Dermatoven APA"},{"key":"B16","first-page":"396","article-title":"Classical type of Fabry disease without angiokeratomas--a case report","volume":"129","author":"Kudumija","year":"2007","journal-title":"Lijec. Vjesn."},{"key":"B17","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1136\/jmg.38.11.769","article-title":"Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier females","volume":"38","author":"MacDermot","year":"2001","journal-title":"J. Med. Genet."},{"key":"B18","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1007\/s40265-019-01090-4","article-title":"Migalastat: a review in Fabry disease","volume":"79","author":"McCafferty","year":"2019","journal-title":"Drugs"},{"key":"B19","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1111\/j.1365-2362.2004.01309.x","article-title":"Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey","volume":"34","author":"Mehta","year":"2004","journal-title":"Eur. J. Clin. investigation"},{"key":"B20","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1016\/j.amjms.2020.07.011","article-title":"When and how to diagnose Fabry disease in clinical pratice","volume":"360","author":"Michaud","year":"2020","journal-title":"Am. J. Med. Sci."},{"key":"B21","doi-asserted-by":"publisher","first-page":"485","DOI":"10.2147\/JMDH.S290580","article-title":"Multidisciplinary management of Fabry disease: current perspectives","volume":"10","author":"Paim-Marques","year":"2022","journal-title":"J. Multidiscip. Healthc."},{"key":"B22","first-page":"15","article-title":"Fabry disease","volume":"47","author":"Paskalev","year":"2011","journal-title":"Meditsinski Pregled\/Medical Rev."},{"key":"B23","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1097\/00004728-200403000-00002","article-title":"Fabry disease:: renal sonographic and magnetic resonance imaging findings in affected males and carrier females with the classic and cardiac variant phenotypes","volume":"28","author":"Ronald","year":"2004","journal-title":"J. Comput. assisted Tomogr."},{"key":"B24","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1002\/humu.9520","article-title":"Novel mutations of the GLA gene in Japanese patients with Fabry disease and their functional characterization by active site specific chaperone","volume":"29","author":"Shimotori","year":"2008","journal-title":"Hum. Mutat."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1007\/s00439-020-02199-3","article-title":"The Human Gene Mutation Database (HGMD\u00ae): optimizing its use in a clinical diagnostic or research setting","volume":"139","author":"Stenson","year":"2020","journal-title":"Hum. Genet."},{"key":"B26","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1186\/s13023-023-02796-1","article-title":"Management of pain in Fabry disease in the UK clinical setting: consensus findings from an expert Delphi panel","volume":"18","author":"Stepien","year":"2023","journal-title":"Orphanet J. Rare Dis."},{"key":"B27","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1007\/bf03401993","article-title":"Twenty novel mutations in the \u03b1-galactosidase A gene causing Fabry disease","volume":"5","author":"Topaloglu","year":"1999","journal-title":"Mol. Med."},{"key":"B28","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1136\/heartjnl-2019-315933","article-title":"Cardiomyopathy associated with the Ala143Thr variant of the \u03b1-galactosidase A gene","volume":"106","author":"Valtola","year":"2020","journal-title":"Heart"},{"key":"B29","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1186\/s13023-022-02192-1","article-title":"Transformative effect of a Humanitarian Program for individuals affected by rare diseases: building support systems and creating local expertise","volume":"17","author":"Verma","year":"2022","journal-title":"Orphanet J. Rare Dis."},{"key":"B30","doi-asserted-by":"publisher","first-page":"107603","DOI":"10.1016\/j.ymgme.2023.107603","article-title":"Global reach of over 20 years of experience in the patient-centered Fabry registry: advancement of Fabry disease expertise and dissemination of real-world evidence to the Fabry community","volume":"139","author":"Wanner","year":"2023","journal-title":"Mol. Genet. Metabolism"}],"container-title":["Frontiers in Genetics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fgene.2024.1415906\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,14]],"date-time":"2024-08-14T06:06:04Z","timestamp":1723615564000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fgene.2024.1415906\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,14]]},"references-count":30,"alternative-id":["10.3389\/fgene.2024.1415906"],"URL":"https:\/\/doi.org\/10.3389\/fgene.2024.1415906","relation":{},"ISSN":["1664-8021"],"issn-type":[{"value":"1664-8021","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,14]]},"article-number":"1415906"}}